Trial Profile
Phase I/II study of RAD001 [everolimus] in combination with temozolomide in patients with advanced pancreatic neuroendocrine tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jul 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 26 Jun 2020 Status changed from active, no longer recruiting to completed.
- 23 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2019.
- 31 Oct 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.